Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients

Curran, Adrian; Gutirerrez, Mar; Deig, Elisabet; Mateo, Gracia; Lopez, Rosa Maria; Imaz, Arkaitz; Crespo, Manuel; Ocaña, Inma; Domingo, Pere; Ribera, Esteban
October 2010
Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2195
Academic Journal
Objectives: To evaluate the virological efficacy, safety, tolerability and pharmacokinetics of a regimen containing 900/100 mg of ritonavir-boosted darunavir once daily in patients with antiretroviral experience but no darunavir resistance.


Related Articles

  • A single centre cohort experience with a new once daily antiretroviral drug. Stebbing, J.; Bower, M.; Holmes, P.; Gazzard, B.; Nelson, M. // Postgraduate Medical Journal;May2006, Vol. 82 Issue 967, p343 

    Background: Atazanavir, an azadipeptide protease inhibitor (PI) with once daily dosing, a lack of insulin resistance, lipid increase, and gastrointestinal toxicities, is approved in combination with other antiretrovirals for the treatment of patients infected with HIV. Unboosted atazanavir is...

  • Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen. Hatano, Hiroyu; Hunt, Peter; Weidler, Jodi; Coakley, Eoin; Hoh, Rebecca; Liegler, Teri; Martin, Jeffrey N.; Deeks, Steven G. // Clinical Infectious Diseases;11/15/2006, Vol. 43 Issue 10, p1329 

    Background. Many treatment-experienced, HIV-infected patients who have limited therapeutic options for complete viral suppression continue to receive a partially suppressive treatment regimen pending the availability of at least 2 new antiretroviral drugs. The major risk of this approach is...

  • Hospitalized HIV-Infected Patients in the HAART Era: A View from the Inner City. Pulvirenti, Joseph J.; Glowacki, Robert; Muppiddi, Uma; Surapaneni, Neelima; Gail, Cheri; Kohl, Becky; Jezisek, Todd // AIDS Patient Care & STDs;Nov2003, Vol. 17 Issue 11, p565 

    To evaluate hospitalizations of HIV-infected patients in the highly active antiretroviral therapy (HAART) era, we analyzed 2736 admissions of 1562 HIV-infected patients to Cook County Hospital from September 20, 1999 to July 10, 2002. Patients were predominantly African American (81%), male...

  • High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy. Goujard, Cécile; Legrand, Mayeule; Panhard, Xavière; Diquet, Bertrand; Duval, Xavier; Peytavin, Gilles; Vincent, Isabelle; Katlama, Christine; Leport, Catherine; Bonnet, Bénédicte; Salmon-Céron, Dominique; Mentré, France; Taburet, Anne-Marie; Goujard, Cécile; Panhard, Xavière; Bonnet, Bénédicte; Salmon-Céron, Dominique; Mentré, France; COPHAR1-ANRS 102 Study Group // Clinical Pharmacokinetics;2005, Vol. 44 Issue 12, p1267 

    Objectives: To describe plasma concentrations of indinavir alone or combined with ritonavir, and of nelfinavir and its active metabolite M8, and to measure their variabilities in HIV-infected patients treated with a stable antiretroviral regimen and experiencing a sustained virological response...

  • Pharmacokinetic enhancement of protease inhibitor therapy. King, Jennifer R.; Wynn, Heather; Brundage, Richard; Acosta, Edward P. // Clinical Pharmacokinetics;2004, Vol. 43 Issue 5, p291 

    Combination antiretroviral therapy with two or more protease inhibitors has become the standard of care in the treatment of HIV infection. Dual protein inhibitor (PI) regimens, such as lopinavir/ritonavir, are commonly used as initial PI therapy. As viral resistance increases and the development...

  • Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy.  // Clinical Infectious Diseases;5/1/2010, Vol. 50 Issue 9, p1275 

    Background. Robust long-term estimates of the risk of development of drug resistance are needed for human immunodeficiency virus (HIV)-infected patients starting combination antiretroviral therapy (cART) regimens currently used in routine clinical practice. Methods. We followed a large cohort of...

  • Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Martinez, V.; Caumes, E.; Gambotti, L.; Ittah, H.; Morini, J.-P.; Deleuze, J.; Gorin, I.; Katlama, C.; Bricaire, F.; Dupin, N. // British Journal of Cancer;4/10/2006, Vol. 94 Issue 7, p1000 

    Highly active antiretroviral therapy (HAART) reduces the incidence and improves the prognosis of Kaposi's sarcoma (KS). This study was designed to identify factors associated with KS clinical responses in HIV-infected patients during HAART. We reviewed the files of 138 HIV-1-infected patients...

  • Analysis of Resistance Testing in South Trinidad. Duke, N.; Aboh, S.; Bosivert, N. // West Indian Medical Journal;2010 Special Issue, Vol. 59 Issue 4, p400 

    The introduction of antiretroviral therapy in Trinidad and Tobago in the 1980s has resulted in a decrease in mortality of HIV-infected persons. Poor adherence to antiretroviral therapy (ART) has resulted in the development of multidrug resistant HIV. Resistance testing done on 40 samples showed...

  • Patient-Reported Outcomes in Virologically Suppressed, HIV-1–Infected Subjects After Switching to a Simplified, Single-Tablet Regimen of Efavirenz, Emtricitabine, and Tenofovir DF. Hodder, Sally L.; Mounzer, Karam; DeJesus, Edwin; Ebrahimi, Ramin; Grimm, Kristy; Esker, Stephen; Ecker, Janet; Farajallah, Awny; Flaherty, John F. // AIDS Patient Care & STDs;Feb2010, Vol. 24 Issue 2, p87 

    A randomized, open-label, multicenter study was conducted to evaluate the therapeutic switch to a single-tablet formulation of efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF) among virologically suppressed, HIV-1–infected subjects. Eligible subjects on stable antiretroviral therapy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics